Pfizer Dividends and Buybacks
Dividend criteria checks 4/6
Pfizer is a dividend paying company with a current yield of 7.85%.
Key information
7.9%
Dividend yield
n/a
Buyback Yield
Total Shareholder Yield | n/a |
Future Dividend Yield | 8.0% |
Dividend Growth | 4.8% |
Next dividend pay date | n/a |
Ex dividend date | n/a |
Dividend per share | US$1.720 |
Payout ratio | 119% |
Recent dividend and buyback updates
Pfizer's (NYSE:PFE) Upcoming Dividend Will Be Larger Than Last Year's
Jan 13Pfizer (NYSE:PFE) Is Paying Out A Larger Dividend Than Last Year
Dec 30Pfizer's (NYSE:PFE) Dividend Will Be Increased To $0.43
Dec 16Recent updates

R&D And Savings Programs Will Strengthen Future Outlook
Apr 08 Focus on R&D productivity in 2025 may risk misalignment with market needs, impacting future revenue if new products underperform.
Oncology Integration And Phase III Trials Will Redefine Future
Apr 07 Pfizer's oncology focus strengthens its portfolio and future revenue through Seagen integration and promising R&D pipeline developments in oncology and vaccines.Pfizer: Shares Stabilize At $25 As Institutions Begin To Load Up (Rating Upgrade)
Mar 28Pfizer: Bulls Need To Check Out Its Graham P/E
Mar 22
Pfizer's Future Depends on Oncology Growth, New Products and operational efficiency
Mar 20I think that Pfizer has a strong pipeline. The aquisition of seagen added many new oncology products that will continue to grow by 14% partially offseting the decline on sales of the covid-19 vaccinesPfizer: Undervalued Safe Haven In Risk-Off Market
Mar 11Pfizer Remains A Good Pick For Dividend Investors
Mar 04Market Still Lacking Some Conviction On Pfizer Inc. (NYSE:PFE)
Feb 28Why Pfizer's Stock Price Isn't Reflecting Its True Value
Feb 19Pfizer: 3 Key Risks That Warrant A Sell
Feb 12Pfizer Q4 Earnings: Solid Results, But Guidance And Patent Concerns Drive The Stock Down
Feb 04These 4 Measures Indicate That Pfizer (NYSE:PFE) Is Using Debt Extensively
Feb 04Pfizer Q4 Earnings Preview: 5 Critical Business Issues To Consider
Jan 28Pfizer's (NYSE:PFE) Upcoming Dividend Will Be Larger Than Last Year's
Jan 13Pfizer: My Top Play In 2025 Using Dogs Of The Dow Strategy
Jan 13Pfizer: One Of The Next Big AI Winners
Dec 30Pfizer (NYSE:PFE) Is Paying Out A Larger Dividend Than Last Year
Dec 30Pfizer: Time And Patience Ran Out (Rating Downgrade)
Dec 24Pfizer: I'm Short-Term Skeptical, Long-Term Positive Post 2025 Guidance Call
Dec 18Pfizer's (NYSE:PFE) Dividend Will Be Increased To $0.43
Dec 16Pfizer: Peer-Leading Dividend And Potential Substantial Shareholder Returns
Dec 11Pfizer: Too Cheap To Ignore
Dec 05Pfizer: High Dividend And Low Price Might Still Offset The Expanding Risks
Nov 21Big Pharma Reckoning Looms With RFK Jr. Eyeing Pfizer
Nov 15Some Investors May Be Willing To Look Past Pfizer's (NYSE:PFE) Soft Earnings
Nov 13Pfizer: Discounted For A Reason - But Dividend Story Remains Rich
Nov 08Pfizer Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next
Nov 01Pfizer Delivers Knockout Q3 Earnings Results, But Investors Are Unimpressed
Oct 29Stability and Growth of Payments
Fetching dividends data
Stable Dividend: PFE's dividends per share have been stable in the past 10 years.
Growing Dividend: PFE's dividend payments have increased over the past 10 years.
Dividend Yield vs Market
Pfizer Dividend Yield vs Market |
---|
Segment | Dividend Yield |
---|---|
Company (PFE) | 7.9% |
Market Bottom 25% (US) | 1.7% |
Market Top 25% (US) | 5.1% |
Industry Average (Pharmaceuticals) | 2.7% |
Analyst forecast (PFE) (up to 3 years) | 8.0% |
Notable Dividend: PFE's dividend (7.85%) is higher than the bottom 25% of dividend payers in the US market (1.69%).
High Dividend: PFE's dividend (7.85%) is in the top 25% of dividend payers in the US market (5.06%)
Earnings Payout to Shareholders
Earnings Coverage: With its high payout ratio (118.6%), PFE's dividend payments are not well covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: With its high cash payout ratio (99.2%), PFE's dividend payments are not well covered by cash flows.
Discover strong dividend paying companies
Company Analysis and Financial Data Status
Data | Last Updated (UTC time) |
---|---|
Company Analysis | 2025/04/14 04:06 |
End of Day Share Price | 2025/04/11 00:00 |
Earnings | 2024/12/31 |
Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package | Data | Timeframe | Example US Source * |
---|---|---|---|
Company Financials | 10 years |
| |
Analyst Consensus Estimates | +3 years |
|
|
Market Prices | 30 years |
| |
Ownership | 10 years |
| |
Management | 10 years |
| |
Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Pfizer Inc. is covered by 51 analysts. 21 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst | Institution |
---|---|
David Toung | Argus Research Company |
Kerry Holford | Berenberg |
Alistair Campbell | Berenberg |